Effects of N-acetylcysteine on regeneration following partial hepatectomy in rats with nonalcoholic fatty liver disease.
Surg Today. 2009.
PMID: 19562447
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 9 |
| 2021 | 8 |
| 2022 | 7 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
Search Results
67 results
Results by year
Citations
7
articles
found by citation matching
N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease.
Hepat Mon. 2010.
PMID: 22308119
Free PMC article.
Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Pharm Biol. 2016.
PMID: 26134756
Search results
Page 1
Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease.
Front Pharmacol. 2023 May 15;14:1186582. doi: 10.3389/fphar.2023.1186582. eCollection 2023.
Front Pharmacol. 2023.
PMID: 37256235
Free PMC article.
Introduction: The continuous rise in the prevalence of nonalcoholic fatty liver disease (NAFLD) is emerging as a global health issue. Although the protective effects of N-acetylcysteine (NAC), an antioxidant, against various diseases have …
Introduction: The continuous rise in the prevalence of nonalcoholic fatty liver disease (NAFLD) is emerging as a …
Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-A pilot study.
J Pediatr Gastroenterol Nutr. 2024 Sep;79(3):652-660. doi: 10.1002/jpn3.12312. Epub 2024 Jul 8.
J Pediatr Gastroenterol Nutr. 2024.
PMID: 38973318
Clinical Trial.
BACKGROUND: Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), and its sequelae of more severe forms such as metabolic dysfunction-associated steat …
BACKGROUND: Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholi …
Drug-induced liver injury.
Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016.
Mayo Clin Proc. 2014.
PMID: 24388027
Review.
There is mixed evidence to support the role of host factors such as age, sex, and chronic liver disease in the development of DILI. For specific drugs, a genetic predisposition appears to be a risk factor for DILI. ...A careful evaluation for other causes of live …
There is mixed evidence to support the role of host factors such as age, sex, and chronic liver disease in the development of …
N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease.
Hepat Mon. 2010 Winter;10(1):12-6. Epub 2010 Mar 1.
Hepat Mon. 2010.
PMID: 22308119
Free PMC article.
METHODS: Thirty patients with non-alcoholic fatty liver steatosis were randomly selected to receive either N-acetylcysteine or vitamin C. ...NAC was able to significantly decrease the span of the spleen. CONCLUSIONS: N-acetylcys …
METHODS: Thirty patients with non-alcoholic fatty liver steatosis were randomly selected to receive either N …
Treatment of nonalcoholic fatty liver disease.
Ann Hepatol. 2002 Jan-Mar;1(1):12-9.
Ann Hepatol. 2002.
PMID: 15114291
Free article.
Review.
Treatment of patients with nonalcoholic fatty liver disease (NAFLD) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidemia. ...Appropriate control of glucose and lipid levels is alway …
Treatment of patients with nonalcoholic fatty liver disease (NAFLD) has typically been focused on the management …
Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants.
Nutr Rev. 2002 Sep;60(9):289-93. doi: 10.1301/002966402320387224.
Nutr Rev. 2002.
PMID: 12296456
Review.
Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver injury ranging from simple steatosis to steatohepatitis, fibrosis, and cirrhosis. ...Currently, treatment is focused on modifying risk factors such as obesity, diabetes m …
Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver injury ranging from simple ste …
Efect of N-acetylcysteine on HepG2 cells which were induced into fatty liver cells.
J Mol Histol. 2024 Dec 4;56(1):27. doi: 10.1007/s10735-024-10313-2.
J Mol Histol. 2024.
PMID: 39630170
Non-alcoholic fatty liver disease is a prevalent liver condition that can progress to fibrosis and cirrhosis. It also poses a risk for hepatocellular carcinoma, underscoring the importance of identifying effective treatments. N- …
Non-alcoholic fatty liver disease is a prevalent liver condition that can progress to fibrosis and …
Activated carbon N-acetylcysteine microcapsule protects against nonalcoholic fatty liver disease in young rats via activating telomerase and inhibiting apoptosis.
PLoS One. 2018 Jan 11;13(1):e0189856. doi: 10.1371/journal.pone.0189856. eCollection 2018.
PLoS One. 2018.
PMID: 29324774
Free PMC article.
Non-alcoholic fatty liver disease (NAFLD) is becoming one of the world's most common chronic liver diseases in childhood, yet no therapy is available that has been approved by the food and drug administration (FDA). ...This study was desi …
Non-alcoholic fatty liver disease (NAFLD) is becoming one of the world's most common chronic liver …
Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Pharm Biol. 2016 Jul;54(7):1198-208. doi: 10.3109/13880209.2015.1060247. Epub 2015 Jul 1.
Pharm Biol. 2016.
PMID: 26134756
Free article.
CONTEXT: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Resveratrol (RSV) and N-acetylcysteine (NAC) are safe representatives of natural and synthetic antioxidants, respectively. ...Animal …
CONTEXT: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Resver …
Treatment of nonalcoholic fatty liver: present and emerging therapies.
Semin Liver Dis. 2001;21(1):81-8. doi: 10.1055/s-2001-12931.
Semin Liver Dis. 2001.
PMID: 11296699
Review.
Nonalcoholic fatty liver associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate metabolic control for patients with diabetes mellitus or hyperlipidemia is always recommended but not …
Nonalcoholic fatty liver associated with obesity may resolve with weight reduction, although the benefits of weight los …
Cite